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editor/peer-reviewers (for the risk of carry-on effects either
positive or negative of the two companion papers).
The TRINOVA-1 solution stays in the middle as in the
primary publication, Monk and co-workers already described
the most important QoL results, but speciﬁed that detailed data
would have been reported in a separate publication [1]. This
strategy may in principle reduce the interest of scientiﬁc editors
and reviewers in the QoL paper; therefore the risk of not pub-
lishing, publishing with delay or publishing in low impact jour-
nals increases. As a consequence, for ever or at least for a long
time, the QoL data will be published with low reporting quality
[6]. This introduces a bias unfavouring the value of PRO in clin-
ical trials.
In conclusion, we propose that a reﬂection should be done by
the editorial scientiﬁc community regarding which is the best
system to allow complete and qualitative reporting of clinical
trials, including all the outcomes that are important for an
exhaustive comprehension of the value of the new drug.
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Diagnostic Gleason score and castration-
resistant prostate cancer
The COU-AA-302 and PREVAIL trials of abiraterone–
prednisone and enzalutamide, respectively, conﬁrmed the efﬁ-
cacy of potent androgen receptor (AR) targeting when com-
pared with placebo in asymptomatic chemotherapy-naive men
with metastatic castration-resistant prostate cancer (mCRPC)
[1, 2]. The COU-AA-301 and AFFIRM trials conﬁrmed efﬁcacy
in symptomatic men who had previously received docetaxel [3,
4]. There are currently no direct prospective comparisons of
either AR targeting agent with other effective treatments for
mCRPC, notably taxane chemotherapy or radium-223. The St
Gallen Advanced Prostate Cancer Consensus Guidelines
Conference in March 2015 [5] reached a consensus that it was
appropriate to extrapolate the results of the COU-AA-302 and
PREVAIL trials to certain symptomatic chemotherapy-naive
men with mCRPC, including patients with visceral metastases,
recognising that symptoms do not inform on which treatment is
most likely to be beneﬁcial. However, the absence of prospective-
ly qualiﬁed predictive biomarkers meant that there was no con-
sensus on recommending strategies for selecting between taxanes
or AR targeting treatments for patients who had not previously
received either treatment.
A number of clinic–pathological features are readily available
to physicians treating mCRPC and several studies have now
evaluated their association with outcome. In a recent issue of
Annals of Oncology, Fizazi et al. [6] assessed the predictive value
of Gleason score (<8 or ≥8) in the two abiraterone regulatory
phase III trials, COU-AA-301 [3] and COU-AA-30 [2]. This is
an important study as Gleason score has been muted as a bio-
marker in mCRPC. Historically, Gleason score has been used as
a standardised risk assessment for biochemical recurrence, de-
velopment of metastases and overall survival (OS) in men with
localised non-castrate prostate cancer. A small study of 381
patients reported that a high initial Gleason score (8–10) at the
time of diagnosis is an independent risk factor for poor response
to abiraterone [7]. Fizazi et al. demonstrated that while Gleason
score of the original diagnostic sample may have weak prognos-
tic value in mCRPC (HR = 1.20; 95% CI 1.03–1.39, P = 0.0221
pre-chemotherapy and HR = 1.17; 95% CI 1.01–1.37, P = 0.04
post-chemotherapy), the beneﬁts from abiraterone compared
with that from prednisone for OS and response were favourable,
irrespective of Gleason score. By leveraging these two large
trials, this analysis provides probably the strongest data to
date of the clinical value of baseline Gleason score in mCRPC. A
post hoc analysis of 482 patients from the TAX327 study
demonstrated a survival beneﬁt and greater PSA declines with
docetaxel in preference to mitoxantrone for cancers with an
initial Gleason score of ≥7, but the beneﬁt was not signiﬁcant
for cancers with a Gleason score of <7 (about a third of the total
number were Gleason score 7–10) [8]. The relevance of the
TAX327 analysis on Gleason score <7 cancers is uncertain given
the smaller number of cancers (and events) in this group and does
not allow comparison with the Fizazi cohort, given the different
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cutoffs and comparator arm treatment. Overall, Gleason score
may provide weak prognostic information. Other features may,
however, be superior. These include a higher neutrophil-to-
lymphocyte ratio that associates with worse outcomes in patients
treated with abiraterone or chemotherapy [9–11]. Moreover, prog-
nostic models could prove more informative than single factors.
Recently, Chi et al. [12] developed and tested a prognostic index
model in 762 post-chemotherapy patients treated with abiraterone
and demonstrated that 6 out of 15 baseline clinic–pathological
factors were the strongest independent predictors of OS. These
factors included lactate dehydrogenase (LDH), ECOG PS, liver
metastases, albumin, alkaline phosphatase and time from the start
of initial androgen-deprivation therapy to start of abiraterone. On
the basis of the number of baseline risk factors, patients were cate-
gorised into three risk groups (good, intermediate and poor), and
different OS rates and 2-year survival probabilities were identiﬁed.
In keeping with the Fizazi study, Gleason score was not sufﬁciently
prognostic to be included in this model.
Given these data, focus should probably shift to response
surrogates and molecular biomarkers. A circulating tumour
cell (CTC) count ≥5/7.5 ml blood (using CellSearch™) was
prognostic in patients treated in the COU-AA-301 study but
arguably more importantly, changes in CTC count and LDH
levels after 12-week treatment were strongly predictive of OS
[13]. These data may be less relevant to earlier stage mCRPC
where fewer CTCs are detected with currently available tech-
nologies. A pre-planned analysis of archival tumour samples
on a subgroup of patients treated in the COU-AA-302 sug-
gested that patients with a hormone-driven TMPRSS2-ERG
gene fusion secondary to deletion and associated duplication
of gene fusion sequences (2 + Edel) could derive the greatest
improvement in radiological progression-free survival and
time to PSA progression [14]. However, the beneﬁt in this
group was not statistically signiﬁcant compared with that in
other ERG classes. Larger datasets would be required to qualify
this biomarker given the prevalence (∼15%) and the moderate
difference in outcome.
Given both abiraterone and enzalutamide directly target AR
signalling, aberrations involving the AR have been studied as
causes of resistance and potentially biomarkers for identifying
resistant patients. Aberrations appear to emerge following the
potent selective pressures of initial androgen-deprivation ther-
apies and molecular characterisation has therefore focused on
real-time studies using liquid biopsies. AR splice variants
lacking the ligand-binding domain that putatively lead to resist-
ance to androgen synthesis inhibitors and AR antagonists (cur-
rently most notably AR-V7) can be detected in CTCs from
patients with advanced mCRPC and associate with resistance to
abiraterone or enzalutamide [15]. In contrast, AR-V7-positive
patients appear to have a better outcome with chemotherapy in
preference to abiraterone or enzalutamide [16], suggesting that this
test could be used for treatment selection. Similarly, patients with
AR gene copy number gain or functionally relevant point muta-
tions (namely T878A or L702H) detected in plasma DNA analyses
have a lower chance of responding to abiraterone or enzalutamide
[17]. Before their implementation into clinical practice, these data
to date reported in small, single-arm cohorts require prospective
qualiﬁcation in randomised trials where a treatment decision is
made based on an analytically robust assay.
Overall on the basis of the current evidence, Gleason score
has no role in treatment selection in mCRPC. Biomarker-driven
multi-institutional studies to describe the landscape of altera-
tions in multidrug-resistant CRPC are informing on the drivers
of resistance and identifying molecular subgroups that can be
targeted therapeutically with novel approaches [18]. Such trans-
lational efforts could lead to personalised treatment strategies
for mCRPC.
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